Effect of an interferon inhibitor on the antiproliferative signal of interferon-alpha

A Aszalos1, K C Chadha, I Stadler

  • 1Division of Research and Testing, Food and Drug Administration, Washington, D.C. 20204.

Biochemical Medicine and Metabolic Biology
|October 11, 1991
PubMed

Insights

Researchers identified a non-antibody interferon (IFN) inhibitor in patients with AIDS, cancer, and lupus. This inhibitor blocks the antiproliferative effects of IFN-alpha and modulates its membrane potential activity.

Area of Science:

  • Immunology
  • Virology
  • Oncology

Background:

  • Non-antibody inhibitors of interferons (IFN) have been previously identified in patients with specific immune-compromising and autoimmune conditions.
  • These inhibitors may play a role in disease pathogenesis by interfering with crucial immune signaling pathways.

Purpose of the Study:

  • To investigate the functional activity of a semipurified non-antibody interferon inhibitor (IFI).
  • To determine the effect of IFI on the antiproliferative signaling of interferon-alpha (IFN-alpha) in a cellular model.

Main Methods:

  • Utilized Daudi cells, a human B lymphoblastoid cell line, to assess IFN-alpha activity.
  • Quantified the antiproliferative effects of IFN-alpha in the presence and absence of the semipurified IFI.
  • Measured the modulation of IFN-alpha's membrane potential shifting ability by the IFI preparation.

Main Results:

  • The semipurified IFI preparation demonstrated the ability to block the antiproliferative signal induced by IFN-alpha in Daudi cells.
  • The interferon inhibitor preparation was shown to modulate the membrane potential shifting ability of IFN-alpha.

Conclusions:

  • A non-antibody interferon inhibitor found in patients with AIDS, cancer, and lupus interferes with key interferon-alpha functions.
  • This inhibitor's capacity to block antiproliferative signals and modulate membrane potential suggests a significant role in immune dysregulation.